Company

Who we are

Alvotech is a privately owned, fully integrated specialty biopharmaceutical company focused exclusively on the development and manufacturing of high-quality biosimilar products ...

Read more

Company

WHAT WE DO

Our biosimilar assets include several biosimilar monoclonal antibodies and fusion proteins that are developed in our research & development centers located across Europe and are manufactured in our state-of-the-art facility in Reykjavik, Iceland ...

Read more

Newsroom

Alvotech and Cipla gulf into a partnership

Alvotech and Cipla Gulf FZ LLC (“Cipla Gulf”), a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla"), today announced that Alvotech and Cipla Gulf have entered into an exclusive partnership for the commercialization of AVT02, an adalimumab biosimilar, in select emerging markets.

Read More

Meet management

World Class team

Alvotech brings together a group of world-class pharmaceutical executives with broad backgrounds and extensive experience in the biopharmaceutical industry. The leadership team is led by Alvotech’s CEO Mark Levick and the company’s founder Robert Wessman ... 

Leadership team

Partnerships

Partnering with Alvotech is gaining access to high quality, ready to market biosimilars


More

We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. Learn more.